GlassScriptPhysician profile
Charles R Warren
NPI 1154389112
$3,292.74
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $620 · 2021: $400 · 2022: $286 · 2023: $641 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.52 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $518.39 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $445.01 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $256.56 | 2019-2022 | |
| Amgen INC. | $211.46 | 2019-2020 | |
| Astellas Pharma US INC | $176.75 | 2019-2021 | |
| Sanofi Pasteur INC. | $158.01 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $151.83 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Abbott Laboratories | $133.52 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $120.36 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $114.90 | 2019-2023 | |
| Amarin Pharma, INC. | $104.89 | 2019-2021 | |
| Lundbeck LLC | $74.04 | 2022-2023 | Rexulti |
| Lilly USA, LLC | $73.22 | 2019-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $69.03 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $64.43 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.76 | 2019 | |
| Idorsia Pharmaceuticals US INC | $57.13 | 2022-2023 | Quviviq |
| Abbvie INC. | $53.47 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $50.00 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $42.95 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $38.85 | 2021-2023 | Euflexxa |
| Xeris Pharmaceuticals, INC. | $38.16 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $36.07 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $34.24 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.95 | 2019-2020 | |
| Daiichi Sankyo INC. | $28.85 | 2019-2021 | |
| Becton, Dickinson and Company | $27.79 | 2023 | Bd Onclarity |
| Otsuka America Pharmaceutical, INC. | $25.74 | 2023 | Rexulti |
| Masimo Corporation | $19.57 | 2021 | |
| Hologic Sales and Service, LLC | $15.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2020 | |
| Circassia INC. | $14.92 | 2020 | |
| Corcept Therapeutics | $14.84 | 2023 | Korlym |
| Shire North American Group INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.